A novel antihypoglycemic role of inducible nitric oxide synthase in liver inflammatory response induced by dietary cholesterol and endotoxemia

Antioxidants and Redox Signaling

Volumn 19, Issue 16, 2013, Pages 1889-1901

  Anavi, Sarit ^a   Hahn Obercyger, Michal ^a   Margalit, Raanan ^b   Madar, Zecharia ^a   Tirosh, Oren ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Science in Action Ltd Weizmann Science Park   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOGEN; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; CHOLESTEROL INTAKE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL DIET; CHOLESTEROL INTAKE; CONTROLLED STUDY; DECOMPOSITION; ENDOTOXEMIA; GENE TRANSFER; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HYDRODYNAMICS; HYPOGLYCEMIA; IN VITRO STUDY; INFLAMMATION; LIVER; LIVER CELL; LIVER INJURY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; WILD TYPE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHARMACOLOGY;

ANIMALS; CHOLESTEROL, DIETARY; ENDOTOXEMIA; HYPOGLYCEMIA; HYPOXIA-INDUCIBLE FACTOR 1; INFLAMMATION; LIPOPOLYSACCHARIDES; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84888615281     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.5157     Document Type: Article

References (39)

1. Abu-Shanab A and Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7: 691-701, 2010
2. Albuszies G, Vogt J, Wachter U, Thiemermann C, Leverve XM, Weber S, Georgieff M, Radermacher P, and Barth E. The effect of iNOS deletion on hepatic gluconeogenesis in hyperdynamic murine septic shock. Intensive Care Med 33: 1094-1101, 2007
3. An Z, Winnick JJ, Farmer B, Neal D, Lautz M, Irimia JM, Roach PJ, and Cherrington AD. A soluble guanylate cyclasedependent mechanism is involved in the regulation of net hepatic glucose uptake by nitric oxide in vivo. Diabetes 59: 2999-3007, 2010
4. Anavi S, Ilan E, Tirosh O, and Madar Z. Infusion of a lipid emulsion modulates AMPK and related proteins in rat liver, muscle, and adipose tissues. Obesity 18: 1108-1115, 2010
5. Bellomo R and Egi M. Hypoglycemia in sepsis: Biomarker, mediator, or both? Crit Care Med 39: 2367-2369, 2011
6. Berry MN and Phillips JW. The isolated hepatocyte preparation: 30 years on. Biochem Soc Trans 28: 131-135, 2000
7. Burgess SC, He TT, Yan Z, Lindner J, Sherry AD, Malloy CR, Browning JD, and Magnuson MA. Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell Metab 5: 313-320, 2007
8. Cauwels A. Nitric oxide in shock. Kidney Int 72: 557-565, 2007
9. Dehne N and Brune B. HIF-1 in the inflammatory microenvironment. Exp Cell Res 315: 1791-1797, 2009
10. Egi M, Bellomo R, Stachowski E, French CJ, Hart GK, Taori G, Hegarty C, and Bailey M. Hypoglycemia and outcome in critically ill patients. Mayo Clin Proc 85: 217-224, 2010
11. Engin A, Zemheri M, Bukan N, and Memis L. Effect of nitric oxide on the hypoglycaemic phase of endotoxaemia. ANZ J Surg 76: 512-517, 2006
12. Farghali H, Hodis J, Kutinova-Canova N, Potmesil P, Kmonickova E, and Zidek Z. Glucose release as a response to glucagon in rat hepatocyte culture: Involvement of NO signaling. Physiol Res 57: 569-575, 2008
13. Feihl F, Waeber B, and Liaudet L. Is nitric oxide overproduction the target of choice for the management of septic shock? Pharmacol Ther 91: 179-213, 2001
14. Folch J, Lees M, and Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509, 1957
15. Fulda S and Debatin KM. HIF-1-regulated glucose metabolism: A key to apoptosis resistance? Cell Cycle 6: 790-792, 2007
16. Hellwig-Burgel T, Stiehl DP, Wagner AE, Metzen E, and Jelkmann W. Review: Hypoxia-inducible factor-1 (HIF-1): A novel transcription factor in immune reactions. J Interferon Cytokine Res 25: 297-310, 2005
17. Ho JJ, Man HS, and Marsden PA. Nitric oxide signaling in hypoxia. J Mol Med (Berl) 90: 217-231, 2012
18. Huang H, Liu T, Rose JL, Stevens RL, and Hoyt DG. Sensitivity of mice to lipopolysaccharide is increased by a high saturated fat and cholesterol diet. J Inflamm (Lond) 4: 22, 2007
19. Kim PK and Billiar TR. Give me iNOS or give me death. Hepatology 34: 436-437, 2001
20. Krinsley JS and Grover A. Severe hypoglycemia in critically ill patients: Risk factors and outcomes. Crit Care Med 35: 2262-2267, 2007
21. Lang CH and Dobrescu C. Sepsis-induced increases in glucose uptake by macrophage-rich tissues persist during hypoglycemia. Metab Clin Exp 40: 585-593, 1991
22. Manco M, Putignani L, and Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 31: 817-844, 2010
23. Mari M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC, and Garcia-Ruiz C. Mitochondrial free cholesterol loading sensitizes to TNF-and Fas-mediated steatohepatitis. Cell Metab 4: 185-198, 2006
24. Meares GP, Hughes KJ, Naatz A, Papa FR, Urano F, Hansen PA, Benveniste EN, and Corbett JA. IRE1-dependent activation of AMPK in response to nitric oxide. Mol Cell Biol 31: 4286-4297, 2011
25. Messarah M, Boumendjel A, Chouabia A, Klibet F, Abdennour C, Boulakoud MS, and Feki AE. Influence of thyroid dysfunction on liver lipid peroxidation and antioxidant status in experimental rats. Exp Toxicol Pathol 62: 301-310, 2010
26. Olson N and van der Vliet A. Interactions between nitric oxide and hypoxia-inducible factor signaling pathways in inflammatory disease. Nitric Oxide 25: 125-137, 2011
27. Powell EE, Jonsson JR, and Clouston AD. Steatosis: Co-factor in other liver diseases. Hepatology 42: 5-13, 2005
28. Rivera N, Ramnanan CJ, An Z, Farmer T, Smith M, Farmer B, Irimia JM, Snead W, Lautz M, Roach PJ, and Cherrington AD. Insulin-induced hypoglycemia increases hepatic sensitivity to glucagon in dogs. J Clin Invest 120: 4425-4435, 2010
29. Schattenberg JM and Galle PR. Animal models of nonalcoholic steatohepatitis: Of mice and man. Dig Dis 28: 247-254, 2010
30. Shinozaki S, Choi CS, Shimizu N, Yamada M, Kim M, Zhang T, Shiota G, Dong HH, Kim YB, and Kaneki M. Liverspecific inducible nitric-oxide synthase expression is sufficient to cause hepatic insulin resistance and mild hyperglycemia in mice. J Biol Chem 286: 34959-34975, 2011
31. Sprangers F, Sauerwein HP, Romijn JA, van Woerkom GM, and Meijer AJ. Nitric oxide inhibits glycogen synthesis in isolated rat hepatocytes. Biochem J 330 (Pt 2): 1045-1049, 1998
32. Spruss A, Kanuri G, Uebel K, Bischoff SC, and Bergheim I. Role of the inducible nitric oxide synthase in the onset of fructose-induced steatosis in mice. Antioxid Redox Signal 14: 2121-2135, 2011
33. Sugita H, Kaneki M, Tokunaga E, Sugita M, Koike C, Yasuhara S, Tompkins RG, and Martyn JA. Inducible nitric oxide synthase plays a role in LPS-induced hyperglycemia and insulin resistance. Am J Physiol Endocrinol Metab 282: E386-E394, 2002
34. Tajima T, Goda N, Fujiki N, Hishiki T, Nishiyama Y, Senoo-Matsuda N, Shimazu M, Soga T, Yoshimura Y, Johnson RS, and Suematsu M. HIF-1alpha is necessary to support gluconeogenesis during liver regeneration. Biochem Biophys Res Commun 387: 789-794, 2009
35. Taylor BS, Alarcon LH, and Billiar TR. Inducible nitric oxide synthase in the liver: Regulation and function. Biochemistry (Mosc) 63: 766-781, 1998
36. Tilg H and Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52: 1836-1846, 2010
37. Tirosh O, Artan A, Aharoni-Simon M, Ramadori G, and Madar Z. Impaired liver glucose production in a murine model of steatosis and endotoxemia: Protection by inducible nitric oxide synthase. Antioxid Redox Signal 13: 13-26, 2010
38. Vetelainen R, van Vliet A, Gouma DJ, and van Gulik TM. Steatosis as a risk factor in liver surgery. Ann Surg 245: 20-30, 2007
39. Wallington J, Ning J, and Titheradge MA. The control of hepatic glycogen metabolism in an in vitro model of sepsis. Mol Cell Biochem 308: 183-192, 2008